The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
This project uses latest genomic technologies to advance our understanding of how bacteria cause disease and finding new antibiotics/approaches to stop the spread of multi-drug resistant hospital superbugs.
Translational Genomics And Combinatorial Drug Discovery To Improve Outcomes For Patients With Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$640,210.00
Summary
Bowel cancer is a major public health burden in Australia. Over the next 5 years, A/Prof Sieber’s research will focus on understanding the molecular pathology of bowel cancer and how this determines the course of disease and response to therapy. Integrated genomic, functional and drug discovery studies will provide significant new insights into fundamental tumour biology and open up new avenues for diagnosis and treatment.
Understanding The Basis Of Autoimmunity In Rheumatoid Arthritis And Type 1 Diabetes To Underpin The Implementation Of Antigen-specific Therapies
Funder
National Health and Medical Research Council
Funding Amount
$847,490.00
Summary
In autoimmune diseases chronic organ-specific or systemic inflammation has devastating and destructing consequences. In rheumatoid arthritis (RA) and type 1 diabetes (T1D), HLA contribute the major genetic susceptibility. HLA proteins present the antigens which underlie disease development. This proposal underpins my vision for development of antigen-specific therapy in RA and T1D, examining interaction between HLA molecules and antigen and disease, and risk markers for T1D development.